Dr. Anas Al-Janadi, MD

Dr. Al-Janadi practices at Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health.

Dr. Al-Janadi's NPI, 1790727360, was assigned on June 11, 2006. Dr. Al-Janadi graduated from Damascus University Faculty of Medicine in 1991. Dr. Al-Janadi holds Michigan license 4301072694.

Dr. Al-Janadi's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth, at 100 Michigan St NE, Grand Rapids, MI 49503 in Kent County. The practice phone is (616) 391-1774.

Dr. Al-Janadi's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health. Dr. Al-Janadi is also affiliated with Corewell Health Gerber Hospital. The medical group on file is Corewell Health Medical Group West. Dmand AI also links Dr. Al-Janadi to 2 more hospitals, 6 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al-Janadi practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Al-Janadi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Al-Janadi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Al-Janadi's licenses on file in 2 states: Michigan and Nevada.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Al-Janadi treats.

CMS data shows 17 Medicare services from Dr. Al-Janadi across 1 procedure code in 2024, all of them office visits, for 25 Medicare patients. Medicare paid $1,068 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 25 Medicare patients who saw Dr. Al-Janadi in 2024. The largest group is 65 to 74, with 11 patients. 72% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al-Janadi's median patient age at 68, with 53% women.

In 2024, Dr. Al-Janadi wrote 161 Medicare Part D claims for 32 patients. 76% of them were for generic drugs. CMS names the drug for 99 of them, across 5 drugs with 11 or more claims each, at $39,265 in total drug cost. In 2023, CMS named 125 claims across 6 drugs.

Dr. Al-Janadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Al-Janadi, published from 2013 to 2024. 2022 was the busiest year, with 2. The most frequent topics are Antibodies, Monoclonal, Antineoplastic Agents and Colonic Neoplasms. Dr. Al-Janadi has published most often in J Clin Oncol. Dr. Al-Janadi's most frequent co-authors are Omar Alkharabsheh, MD, Peter C. Kurniali, MD and Sreenivasa R. Chandana, MD.

Dmand AI links Dr. Al-Janadi to 4 clinical trials. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Breast Neoplasms, Male and Hemoglobinuria, Paroxysmal. Open Payments lists research payments to Dr. Al-Janadi that name 1 trial.

CMS Open Payments shows 455 general payments to Dr. Al-Janadi from 38 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 47% of the total. Genentech, Inc. paid the most, $91,787. It also lists 1 research payment totaling $900 in 2019, naming 1 clinical trial.

Dr. Al-Janadi graduated from Damascus University Faculty of Medicine in 1991. Dr. Al-Janadi is a member of ASCO and ASH.

Dr. Al-Janadi is in network with 12 carriers, including Aetna, Health Alliance Plan and Priority Health. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.